2 Clarke Drive
Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Maha Hussain, MD, FACP, FASCO, discusses the clinical impact of the phase 3 PROfound trial in metastatic castration-resistant prostate cancer.
Maha Hussain, MD, FACP, FASCO, Genevieve E. Teuton Professor of Medicine, Division of Hematology and Oncology, Deputy Director, Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, discusses the clinical impact of the phase 3 PROfound trial in metastatic castration-resistant prostate cancer (mCRPC).
Despite crossover, the final overall survival (OS) analysis of the PROfound trial, which was presented during the 2020 ESMO Virtual Congress, demonstrated improved OS with the PARP inhibitor olaparib (Lynparza) versus enzalutamide (Xtandi)/abiraterone acetate (Zytiga) in patients with mCRPC who harbor homologous recombination repair gene alterations.
According to Hussain, these findings represent a significant shift in the treatment of men with mCRPC.
Historically, patients with mCRPC were treated with one-size-fits-all regimens, Hussain explains. For example, patients who receive chemotherapy and hormone therapy are not preselected.
The PROfound trial demonstrated the feasibility of personalizing treatment for patients with specific genomic abnormalities, Hussain says.
Moreover, moving away from generic management strategies in all-comers can spare some patients who are eligible for more targeted therapy approaches unnecessary exposure to less effective treatments, concludes Hussain.